US 12,570,725 B2Granted

ZIKA antibodies and their use

AssigneeDuke University

InventorsSallie Permar, Mattia Bonsignori, Tulika Singh, Kwan-Ki Hwang

Life of this patent

Estimating the term…

Loading patent…

Abstract

The invention is directed to antibodies, and antigen-binding fragments thereof, that potently neutralize infection of ZIKV. The invention also relates to antigenic sites to which the antibodies and antigen-binding fragments bind, as well as to nucleic acids that encode the antibodies of the invention, and immortalized B cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of ZIKV infection.

Claims15

Dependent claims

A recombinant Zika antibody or the antigen-binding fragment thereof, as selected from the group consisting of:

119-4-D6.01 having a VH consisting of H621098 with the amino acid sequence of SEQ ID NO:
30 and a VL consisting of K620748 with the amino acid sequence of SEQ ID NO:
40, 119-4-D6.02 having a VH consisting of H621098 with the amino acid sequence of SEQ ID NO:
30 and a VL consisting of L620584 with the amino acid sequence of SEQ ID NO:
47, 119-4-D6.03 having a VH consisting of H621098 with the amino acid sequence of SEQ ID NO:
30 and a VL consisting of L620585 with the amino acid sequence of SEQ ID NO:
48, DH1017.IgM having a VH consisting of H592679 with the amino acid sequence of SEQ ID NO:
35 and a VL consisting of L590920 with the amino acid sequence of SEQ ID NO:
50, and DH1017.IgG, having a VH consisting of H592679 with the amino acid sequence of SEQ ID NO:
35 and a VL consisting of L590920 with the amino acid sequence of SEQ ID NO:
50.

8 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/642,674Filed 11 Sep 2020 · us provisional application
Priority: 13 Sep 2019
Published: US 2022/0315646 A16 Oct 2022
Granted: 10 Mar 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification17 codes

C07K 16/10
Against material from viruses: rNA viruses
A61P 31/14
Antivirals: for RNA viruses
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies
A61K 2039/55
Medicinal preparations containing antigens or antibodies: characterised by the host/recipient, e.g. newborn with maternal antibodies

Family

Application62/900,201Us provisional application · filed 13 Sep 2019
US 2022/0315646 A1Pre-grant publication · published 6 Oct 2022
US 12,570,725 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key